These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1311080)

  • 1. [Treatment of venous thrombosis with low molecular weight heparin and fluindione].
    Fiessinger JN; Paul JF; Alhenc-Gelas M; Veyssier C; Martin JB; Aiach M
    Presse Med; 1992 Jan; 21(2):65-8. PubMed ID: 1311080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early versus delayed introduction of oral vitamin K antagonists in combination with low-molecular-weight heparin in the treatment of deep vein thrombosis. a randomized clinical trial. The ANTENOX Study Group.
    Leroyer C; Bressollette L; Oger E; Mansourati J; Chèze-Le Rest C; Nonent M; Buchmuller A; Tardy B; Decousus H; Parent F; Simonneau G; Juste K; Ill P; Abgrall JF; Clavier J; Mottier D
    Haemostasis; 1998; 28(2):70-7. PubMed ID: 10087431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized versus non-personalized computerized decision support system to increase therapeutic quality control of oral anticoagulant therapy: an alternating time series analysis.
    Colombet I; Bura-Rivière A; Chatila R; Chatellier G; Durieux P;
    BMC Health Serv Res; 2004 Sep; 4(1):27. PubMed ID: 15456515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
    Harenberg J; Schmidt JA; Koppenhagen K; Tolle A; Huisman MV; Büller HR
    Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
    Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
    Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of left intraventricular thrombosis with low molecular weight heparin].
    Meurin P; Renaud N; Weber H; Tabet JY; Grosdemouge A; Bourmayan C; Ben Driss A
    Arch Mal Coeur Vaiss; 2003 Apr; 96(4):311-5. PubMed ID: 12741307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
    N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group.
    Hamulyák K; Lensing AW; van der Meer J; Smid WM; van Ooy A; Hoek JA
    Thromb Haemost; 1995 Dec; 74(6):1428-31. PubMed ID: 8772214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Home therapy with LMWH in deep vein thrombosis: randomized study comparing single and double daily administrations.
    Bellosta R; Ferrari P; Luzzani L; Carugati C; Cossu L; Talarico M; Sarcina A
    Angiology; 2007; 58(3):316-22. PubMed ID: 17626986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Which antithrombotic agents should be prescribed in deep venous thrombosis of the limbs?].
    Fiessinger JN
    Presse Med; 1994 Mar; 23(11):509-10. PubMed ID: 8022737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical venous limb gangrene complicating oral anticoagulation in a patient with cancer-associated deep venous thrombosis.
    Georgin S; Pouchot J; Raschilas F; Barete S; Lerolle DL; Vinceneux P
    Arch Dermatol; 2003 Sep; 139(9):1126-8. PubMed ID: 12975152
    [No Abstract]   [Full Text] [Related]  

  • 13. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.
    Hull R; Raskob G; Pineo G; Rosenbloom D; Evans W; Mallory T; Anquist K; Smith F; Hughes G; Green D
    N Engl J Med; 1993 Nov; 329(19):1370-6. PubMed ID: 8413432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting daily maintenance dose of fluindione, an oral anticoagulant drug.
    Cazaux V; Gauthier B; Elias A; Lefebvre D; Tredez J; Nguyen F; Cambus JP; Boneu B; Boccalon H
    Thromb Haemost; 1996 May; 75(5):731-3. PubMed ID: 8725714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    Koopman MM; Prandoni P; Piovella F; Ockelford PA; Brandjes DP; van der Meer J; Gallus AS; Simonneau G; Chesterman CH; Prins MH
    N Engl J Med; 1996 Mar; 334(11):682-7. PubMed ID: 8594426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.
    Kearon C; Ginsberg JS; Julian JA; Douketis J; Solymoss S; Ockelford P; Jackson S; Turpie AG; MacKinnon B; Hirsh J; Gent M;
    JAMA; 2006 Aug; 296(8):935-42. PubMed ID: 16926353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic efficacy of the vitamin K antagonist fluindione in a human Ex vivo model of arterial thrombosis : effect of anticoagulation level and combination therapy with aspirin.
    Bossavy JP; Sakariassen KS; Thalamas C; Boneu B; Cadroy Y
    Arterioscler Thromb Vasc Biol; 1999 Sep; 19(9):2269-75. PubMed ID: 10479672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    Levine M; Gent M; Hirsh J; Leclerc J; Anderson D; Weitz J; Ginsberg J; Turpie AG; Demers C; Kovacs M
    N Engl J Med; 1996 Mar; 334(11):677-81. PubMed ID: 8594425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
    Fiessinger JN; Huisman MV; Davidson BL; Bounameaux H; Francis CW; Eriksson H; Lundström T; Berkowitz SD; Nyström P; Thorsén M; Ginsberg JS;
    JAMA; 2005 Feb; 293(6):681-9. PubMed ID: 15701909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
    Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.